Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Combination therapy for treating breast cancer
US9539325B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9539325-B2 |
| Application number | US-201414562306-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 5, 2014 |
| Priority date | Mar 12, 2010 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition to treat a breast cancer in a subject, comprising: a therapeutically effective amount of a Transforming Growth Factor beta (TGFβ) antagonist, capecitabine, and ixabepilone, wherein said TGFβ antagonist is present in an amount effective to enhance the efficacy of capecitabine and ixabepilone to treat said breast cancer. 2. The composition of claim 1 , wherein said TGFβ antagonist is an agent that blocks the binding of a TGFβ protein to its receptor. 3. The composition of claim 2 , wherein said agent is a protein. 4. The composition of claim 3 , wherein said agent is an anti-TGFβ antibody. 5. The composition of claim 4 , wherein said antibody is a pan neutralizing anti-TGFβ antibody. 6. The composition of claim 4 , wherein said antibody is an anti-TGFβ monoclonal antibody. 7. The composition of claim 6 , wherein said antibody is a humanized antibody that comprises one or more CDRs of 1D11. 8. The composition of claim 2 , wherein said TGFβ protein is TGFβ-1, -2, -3, or a combination thereof. 9. A kit to treat a breast cancer in a subject, comprising: a therapeutically effective amount of a Transforming Growth Factor beta (TGFβ) antagonist, capecitabine, and ixabepilone, wherein said TGFβ antagonist is present in an amount effective to enhance the efficacy of capecitabine and ixabepilone to treat said breast cancer. 10. The kit of claim 9 , wherein said TGFβ antagonist is an agent that blocks the binding of a TGFβ protein to its receptor. 11. The kit of claim 10 , wherein said agent is a protein. 12. The kit of claim 11 , wherein said agent is an anti-TGFβ antibody. 13. The kit of claim 12 , wherein said antibody is a pan neutralizing anti-TGFβ antibody. 14. The kit of claim 13 , wherein said antibody is an anti-TGFβ monoclonal antibody. 15. The kit of claim 14 , wherein said antibody is a humanized antibody that comprises one or more CDRs of 1D11. 16. The kit of claim 10 , wherein said TGFβ protein is TGFβ-1, -2, -3, or a combination thereof.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for metastasis · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Antineoplastic agents · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9539325B2 cover?
- The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
- Who is the assignee on this patent?
- Genzyme Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/505. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).